visit our website: www.flemingeurope.com Pharma Exabyte 2015 Shaping the Next Generation Pharmaceutical R&D with Big Data </27-28 May 2015> <Berlin = “Germany”> <event overview/.> Big data is a new frontier for pharmaceutical companies. Its potential in research and development is enormous and it presents endless opportunities for every stage of a drug’s development. Pattern identification, predictive modelling, and more efficient, diversified-criteria-based clinical trials are only some of the possibilities big data opens to pharma companies. However, full integration of such capabilities requires operational and organizational transformations that most companies are still hesitant to implement. Furthermore, there is a very limited number of case studies available to learn from. This event aims to do just that: bring experts who can offer you knowledge on what, how and when it can be done. </what to expect> 18+ speakers and panelists case studies keynote speeches best practices from other industry practical examples enhanced networking opportunities a different format securing more interactivity intensive discussions boosted by our special features: •panel discussions •The Idea Market •focused round table discussions •Fishbowl discussions </OUR EXPERT SPEAKER & PANELIST FACULTY> Chris Day, AstraZeneca, UK Vice President Solution Delivery and Maintenance Joaquin Dopazo, Centro De Investigacion Principe Felipe, Spain Head of the Computational Genomics Department Manuel Martin Marquez, CERN, Switzerland Senior Research Fellow & Data Scientist Mathias Ganz, Ipsen, France Vice President R&D IT Hugo Ceulemans, Janssen, Belgium Associate Scientific Director, Computational Systems Biology Athula Herath, MedIummune, UK Statistical Director Martin Ryzl, Merck, CZ GIC Analytics Platform Engineering Pantaleo Nacci, Novartis Vaccines, Italy Head Statistical Safety and Epidemiology/PV TBC Jerry Lanfear, Pfizer, UK Head of Research Business Technologies, Europe Dr Andreas Bender, University of Cambridge, UK Lecturer for Molecular Informatics and Drug Design 011000010110110101110011011101000110010101110010011001000110000101101101 tel.: +421 257 272 120, fax: +421 255 644 490 [email protected], www.flemingeurope.com (may 27=[wednesday]) 8:30 Registration & Coffee • What are the opportunities for different R&D stages? • Is Big Data going to cure the stagnant pipeline and declining success rates? • What role will Big Data play in the future? 9:50 Keynote: A special insight from other industry • Deployment of big data solutions: advice and limitations • Reducing operational costs through big data processes • Success stories Manuel Martin Marquez, CERN, Switzerland Senior Research Fellow & Data Scientist 10:20[morning coffee] << & networking; Addressing the aspects of Big Data: the 3Vs and beyond Volume Speed, punchy presentations to start with. Short presentations delivered by representatives from translational medicine, clinical research, genomics and drug discovery. Four different opinions on the Volume will help you to uncover: • Implication of Big Data in the early phase of drug development • How to store, handle, reduce and utilize complex data in translational medicine • Strategies to eliminate volume-related challenges • Leveraging large amounts of data to advance patient-centric treatment • Next generation of bioinformatics to accelerate the development of promising treatments 10:50 Statistical Landscaping of therapeutics effects for the Personal Genomics Era • Begin with the end in mind, i.e. construct the landscape of health and treatment outcomes • Establishing the foundations for mapping personal genomes into the fold to make precise inferences about the optimal personalised healthcare interventions • Utilising the foundation for translation from the bed side to bench and back of optimal therapeutic interventions and healthcare decision making processes Athula Herath, MedIummune, UK Statistical Director 11:30 An in-depth panel discussion with our speakers on-spot to dig deeper into: • Validating biological targets through big data • Utilization of big data in translational medicine • Reducing complex data Velocity 12:00 Speed presentations delivered by representatives from translational medicine, clinical research, genomics and drug discovery. Four different opinions will cover: Use of wearables to collect data in real time • Potential of devices such as smartphones or Google Glass • Processing exponential ,too large, raw and amorphous data • How to deal with the challenge of velocity for input data? • Creating dynamic sample size estimations in response to emerging clinical trial data DAY Following the morning presentations, participants will split into groups and will further discuss the already presented topics. Each table will have a moderator and three main questions to discuss. After 15 minutes the groups will swap three members with another table and the discussion will go on with the ideas - brought from the different group. Each moderator will then present the main outcomes to all attendees. Opening Remarks from the Event Chair 9:10 ‚Speed dating session‘: exchange of business cards among all participants 9:20 {Opening Keynote++} Are we ready for the era of Big Data? FORUM 12:40 The Idea Market 9:00 Welcome Note from Fleming Europe MAIN 13:10{<<luncheon<<} Variety Three different speeches, Three different insight on: • Use of combined sources to develop drugs for specific patient populations • Pooling data from multiple sources to tailor treatments • Use of combined sources to customize drug development • Discovering new biomarkers through digital pathology 14:10 Large scale and holistic compound scale activity prediction • 2D, 3D, physicochemical, high-content imaging and transcriptomics data at large scale (100k-10M cpds) • HPC-enabled machine learning • Joined prediction of activities in 1000s of target-assigned or liabilityassociated assays Hugo Ceulemans, Janssen, Belgium Associate Scientific Director, Computational Systems Biology 14:50 Panel discussion with our speakers to further investigate: • • • • Measuring the impact of big data on R&D Tools for big data management, analysis and visualization Implementation of Big Data infrastructure Linking structured and semi-structured internal data with unstructured external data to generate Big Data analytics Veracity, Volatility & Validity 15:20 Spotlight session on uncertainty of data 3 speed presentations followed by a short wrap-up and time for Q&A • Combining scientific literature with internal and external data • Unstructured data, uncertain value, expensive exploration • Creating a semantic data model as a layer 16:00[afternoon tea] << & networking; 16:30 Closing keynote: A look into the future of medicine The Virtual Human: In-Silico Methods for Personalised Medicine • use of high performance computing to develop personalised drugs based on a patient’s specific genome • in silico clinical trials • modelling and simulation of organ systems for clinical interventions 17:00 The Fishbowl discussion A 360 degree debate to sum up the main points discussed We will have 5 chairs arranged in an inner circle (‘the fishbowl’) and will start with a ‘closed fishbowl’ with the 5 chairs filled by our Moderator and Speakers. The audience outside the fishbowl will first listen in on the discussion and then we will switch to an ‘open fishbowl’ where one chair will be left empty. Any member of the audience can, at any time, occupy the empty chair and join the fishbowl. When this happens, an existing member of the fishbowl will voluntarily leave the fishbowl. The discussion continues allowing several people to participate in a focused conversation! Topics considered for inclusion: • Impact of next generation sequencing technologies on genomics • Treating patients, not diseases • Real World data and studies: How is Real World Data commuting to translational aspects of R&D 17:45Closing Remarks from the Chairman Speakers, Delegates and Sponsors are cordially invited to attend the Cocktail Networking Reception 011000010110110101110011011101000110010101110010011001000110000101101101 tel.: +421 257 272 120, fax: +421 255 644 490 [email protected], www.flemingeurope.com (may 28=[thursday]) MAIN FORUM DAY 8:30 Registration & morning coffee 12:10{<<luncheon<<} 9:00 Opening remarks from the Chairman 13:10 Focused round table discussions • Changing the mind-set, pursuing a big-data change program and creating a successful data-centric culture – gaining value BEFORE identifying an ideal future state The group will break into smaller groups, each discussing a different issue. Every group will be led by a round-table leader, who will lead a lively discussion, ask questions, spice it up with some controversy and create an open, uncompetitive atmosphere for idea sharing. At the conclusion, every chair will summarize the findings of their discussion and present to the rest of the audience. • Definition of clear goals The discussion topics are as follows: 9:10 Opening keynote: Creating Data-Centric Culture in an organization • Understanding the real value of big data 1. Oncology Effective utilization of big data in various therapeutic areas 9:40Oncology Case study: From conventional to a perfect cancer drug 2. Rare diseases 3. Immunology 4. Neurology 13:50 Data Security: Facing the challenge • Finding the right drug with the help of cloud computing • Setting up information management processes to avoid legal and ethical pitfalls while delivering quality data • Speeding up the process to identify the right medicine through predictive analytics platforms • Ensuring the accuracy and timeliness of data • data governance issues related to clinical trials(electronic health records, storage system for clinical data, real world evidence in trial design) • What are the struggles with implementation? 10:10[morning coffee] << & networking; 10:40 Rare diseases Case study: Big data to unlock rare disease’s secret 14:20 The Fishbowl discussion A 360 degree debate to sum up the main points discussed We will have 5 chairs arranged in an inner circle (‘the fishbowl’) and will start with a ‘closed fishbowl’ with the 5 chairs filled by our Moderator and Speakers. The audience outside the fishbowl will first listen in on the discussion and then we will switch to an ‘open fishbowl’ where one chair will be left empty. Any member of the audience can, at any time, occupy the empty chair and join the fishbowl. When this happens, an existing member of the fishbowl will voluntarily leave the fishbowl. The discussion continues allowing several people to participate in a focused conversation! • Use large stores of information to identify a genetic mutation • From hypothesis to confirmation through data analysis • Digital health possibilities enabled though viral blogs and other means Joaquin Dopazo, Centro De Investigacion Principe Felipe, Spain Head of the Computational Genomics Department 11:10Immunology Case study: Prediction of immunology-related disease progression Topics considered for inclusion: • Predicting disease progression in patients with established disease from a multi-year registry data set • How do you open the clinical data to other scientists? • Cross-functional collaboration to support/allow successful decision-making • Utilization of patient-administered survey and annual in-person patient visit • Analytics as a tool of Data Visualization • Securing competitive advantage through strategic partnerships with patients, the public and industry, innovative collaboration projects between CROs (or other vendors) and sponsors 11:40Neurology Case study: The Brain Initiative • New dynamic picture of the brain through accelerating the development and application of innovative technologies 15:00Closing Remarks from the Chairman • Big data as a key to treat, cure, and even prevent brain disorders • Discovering fundamental insights and addressing brain diseases through neuron mapping [farewell] << & networking;
© Copyright 2024